Novartis AG (NVS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and good afternoon and welcome to the Novartis Q1 2025 results release conference call and live webcast. Please note that during the presentation all participants will be in a listen only mode and the conference is being recorded. After the presentation there will be an opportunity to ask questions by pressing star 1 1 at any time during the conference. please limit yourself to one question and return to the queue for any follow-ups. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Ms. Sloane Simpson, Head of Investor Relations. Please go ahead, madam. Thank you, Heidi. Good morning and good afternoon, everyone, and welcome to our Q1 2025 earnings call. The information presented today contains forward-looking statements that have involved known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-S and its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission. Before we get started, I just want to reiterate Heidi's guidance. For our analysts, please limit yourselves to one question at a time, and we'll cycle through the queue as many times as we can. And with that, I will hand over to Vas. Thank you, Sloan. And thanks, everyone, for joining today's conference call. If we could move forward to slide four. Novartis delivered double-digit sales growth in the quarter, a really strong start to the year. We had robust margin expansion...